Payment overview · 2025
General Payments
$112.52
2 reported records · 2 companies
Healthcare provider profile · identity verified
Alaa Al Saif, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MASSILLON, OH · NPI 1730332909
Verified facts
What the public records show
CMS Open Payments records show Alaa Al Saif, M.D. received $112.52 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 85.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.14 | 85.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.38 | 14.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $112.52 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 769 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 663 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 642 | 170 |
| Lisinopril | Lisinopril | 501 | 140 |
| Omeprazole | Omeprazole | 374 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 99 |
| Metformin Hcl | Metformin Hcl | 351 | 97 |
| Losartan Potassium | Losartan Potassium | 307 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 297 | 79 |
| Trazodone Hcl | Trazodone Hcl | 262 | 66 |
| Simvastatin | Simvastatin | 258 | 75 |
| Gabapentin | Gabapentin | 238 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 48 |
| Furosemide | Furosemide | 178 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 172 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 167 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 38 |
| Tramadol Hcl | Tramadol Hcl | 154 | 36 |
| Carvedilol | Carvedilol | 153 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 39 |
| Methylprednisolone | Methylprednisolone | 133 | 99 |
| Potassium Chloride | Potassium Chloride | 129 | 37 |
| Eliquis | Apixaban | 127 | 33 |
| Sertraline Hcl | Sertraline Hcl | 124 | 29 |
| Alprazolam | Alprazolam | 123 | 27 |
| Montelukast Sodium | Montelukast Sodium | 117 | 33 |
| Amoxicillin | Amoxicillin | 113 | 86 |
| Allopurinol | Allopurinol | 112 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 38 |
| Lorazepam | Lorazepam | 98 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 90 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 27 |
| Famotidine | Famotidine | 86 | 23 |
| Prednisone | Prednisone | 86 | 52 |
| Glimepiride | Glimepiride | 84 | 25 |
| Mometasone Furoate | Mometasone Furoate | 84 | 47 |
| Methocarbamol | Methocarbamol | 82 | 38 |
| Ezetimibe | Ezetimibe | 80 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 77 | 30 |
| Buspirone Hcl | Buspirone Hcl | 76 | 29 |
| Cephalexin | Cephalexin | 73 | 56 |
| Jardiance | Empagliflozin | 73 | 24 |
| Valsartan | Valsartan | 72 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 26 |
| Metformin Hcl Er | Metformin Hcl | 71 | 23 |
| Warfarin Sodium | Warfarin Sodium | 71 | 18 |
| Meloxicam | Meloxicam | 70 | 28 |
| Januvia | Sitagliptin Phosphate | 65 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 19 |
| Celecoxib | Celecoxib | 63 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 17 |
| Synthroid | Levothyroxine Sodium | 62 | 15 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 16 |
| Mirtazapine | Mirtazapine | 56 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Lovastatin | Lovastatin | 53 | 14 |
| Spiriva Respimat | Tiotropium Bromide | 53 | 14 |
| Pregabalin | Pregabalin | 51 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 22 |
| Ozempic | Semaglutide | 48 | 14 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 12 |
| Glipizide | Glipizide | 41 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 31 |
| Atenolol | Atenolol | 40 | 13 |
| Finasteride | Finasteride | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 19 |
| Clonidine Hcl | Clonidine Hcl | 38 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Azithromycin | Azithromycin | 36 | 29 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 16 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 11 |
| Naproxen | Naproxen | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 15 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 11 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Digoxin | Digoxin | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Lotrel | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $112.52 · 2 records | PFIZER INC. | NURTEC ODT, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error